Brind.
  1. Bristol Myers Squibb and SystImmune, Inc. announced a collaboration to jointly develop iza-bren, with data presentation scheduled at the WCLC Annual Meeting in Barcelona, Spain.

Dr. Salter-Cid led teams at Bristol Myers Squibb on June 1, 2026.

2 reports, 2 independent Updated Jun 10
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Dr. Salter-Cid led teams at Bristol Myers Squibb on June 1, 2026.

Who's involved

What this event is mainly about
Bristol-Myers Squibbscientific advisor

How it developed

Newest first. Tap a step to see who reported it.
  1. Dr. Salter-Cid appointed CSO and VP/Head of Immunology at Bristol-Myers Squibb.1 source
  2. Dr. Salter-Cid led teams at Bristol Myers Squibb on June 1, 2026.1 source

Keep exploring

Part of

Bristol Myers Squibb and SystImmune, Inc. announced a collaboration to jointly develop iza-bren, with data presentation scheduled at the WCLC Annual Meeting in Barcelona, Spain. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped